Recommendation in Wall Street's Best Investments
Prior Dick Davis Digest
featured PRED in the May 15th publication issue 817 page 12-13
the recommendation was from www.saadvisory.com
www.saadvisory.com see April 22 and 29 2019 email alert
We remain extremely bullish as the flow of pressers continue to create stronger and stronger building blocks for this potential blockbuster
Sure PRED is not going straight up, but don't get left at the train station.
We have NASDAQ listing (already baked in)
2.assume brokerage alignment rapidly after confirmation of listing
3.institution participation
4. partnerships, acquisitions, joint ventures
5.endometriosis test kits
6. OA trial and ready for FDA Introduction
7.Plus many other things that are going surface
Prior Dick Davis Digest
featured PRED in the May 15th publication issue 817 page 12-13
the recommendation was from www.saadvisory.com
www.saadvisory.com see April 22 and 29 2019 email alert
We remain extremely bullish as the flow of pressers continue to create stronger and stronger building blocks for this potential blockbuster
Sure PRED is not going straight up, but don't get left at the train station.
We have NASDAQ listing (already baked in)
2.assume brokerage alignment rapidly after confirmation of listing
3.institution participation
4. partnerships, acquisitions, joint ventures
5.endometriosis test kits
6. OA trial and ready for FDA Introduction
7.Plus many other things that are going surface
From almost 9 months ago ($1.16 p/s)...
My 12 month target is 10
My long term target is 100 ( 3-5 years )
No problem. I'm right there with him...Started buying at $1.19, bought a good bit at $.88, loaded up again at $2, and have been buying the dips ever since. $1.60ish average on all shares, and I don't plan to sell any for quite some time...Will consider unloading a little to ride freebies at $15+, but if/when we get to $5, DD price could come fairly quick....
Continued success to us. Enjoy the ride...
Predictive Technology Group Reports Third Quarter Fiscal 2019 Financial Results
Nine-month revenue increased 217% to $30 million with $3.1 million in positive cash flow from operations
Email Print Friendly Share
May 21, 2019 09:00 ET | Source: Predictive Technology Group, Inc.
SALT LAKE CITY, May 21, 2019 (GLOBE NEWSWIRE) -- Predictive Technology Group, Inc. (OTC PINK: PRED) (the Company), a leader in the use of data analytics for disease identification and subsequent therapeutic intervention through precision therapeutic treatments, reports financial results for the three and nine months ended March 31, 2019 and provides a business update.
Management Commentary
“I’m pleased to report our 10[SUP]th[/SUP] consecutive quarter of sequential growth in revenue. Third quarter fiscal 2019 revenue of $11.3 million was up 167% over the third quarter of fiscal 2018,” said Bradley Robinson, CEO of Predictive Technology Group. “Revenue for the first nine months of fiscal 2019 exceeded $30 million, up 217% over the year-ago period, and we generated $3.1 million in cash flow from operations.
“We have made exceptional progress in building a strong infrastructure to support the development and commercialization of our proprietary genetic-based diagnostics and therapeutics,” he added. “Predictive Biotech is now operating in our recently opened, state-of-the-art production laboratory and R&D facility that was expanded to meet the production and sales needs of our human cell and tissue products for use in cellular therapies and regenerative medicine. We also finalized the integration of Taueret Laboratories and Inception Dx into Predictive Laboratories, providing us with a CAP/CLIA-accredited laboratory for processing our genetic-based tests. We strengthened our Board with the appointment of independent directors with exceptional industry, public affairs, financial and governance experience. More recently we submitted an application to list Predictive common stock for trading on the NASDAQ, a move that we believe will generate increased visibility and credibility for our Company.”
Third Quarter and Recent Highlights
Corporate Developments
- Integrated the sales and marketing team from FlagshipHealth Group, previously a consultant contractor, to support commercial activities for Predictive Biotech and Predictive Laboratories through combined domestic direct sales and a nationwide distributor network.
- Named Sen. Orrin G. Hatch, Ronald Barhorst and Jay M. Moyes to its Board of Directors, expanding its Board to six including four independent directors.
- Submitted an application to list its common stock to trade on the NASDAQ.
- Completed the acquisition of Taueret Laboratories, LLC, a provider of genetic testing and DNA analysis services through its CAP/CLIA-certified laboratory, to provide for faster entry into the high-growth women’s health testing market with proprietary commercial products.
- Integrated over $5 million of recently purchased new genomics equipment and supplies into laboratory to expand the technical capabilities and capacities.
- Appointed Christine Seward, MS, CGC as Senior Vice President of Sales and Marketing of Predictive Laboratories, bringing extensive experience commercializing molecular diagnostics including products in the reproductive space from her 16 years at Myriad Genetics.
- Announced former Taueret Laboratories Chief Operations Officer Lesa Nelson and Director of Quality Control Debbie Dyckman joined Predictive Laboratories.
- Launched ARTguide™ genetic test for reproductive endocrinologists into 14 Key Opinion Leader (KOL) clinics to refine the test ordering and reporting processes.
- Presented a poster titled The Genetic Architecture of Endometriosis at the Society for Reproductive Investigation (SRI) meeting, demonstrating the ability of the proprietary genetic test ENDORisk™ to segregate patients with endometriosis from those without in the Caucasian population with a high degree of sensitivity (Area Under the ROC Curve = 0.91). The mean genetic risk score for endometriosis was 1.6 in the general population versus 5.3 in endometriosis patients, determined to be statistically significant with a p-value of less than 0.001.
- Reported 10[SUP]th[/SUP] consecutive quarter-over-quarter revenue growth.
- Completed buildout of a new 2,000-square-foot production laboratory and R&D facility meeting good manufacturing Practice (GMP) and Good Tissue Practice (GTP) requirements for Predictive Biotech. The lab features an ISO 7 cleanroom and 18 ISO 5 production hoods.
Revenue for the third quarter of fiscal 2019 was $11.3 million, an increase of 167% from $4.2 million for the third quarter of fiscal 2018. The increase was due to continued growth in the sales volume and increasing demand for human cell and tissue products.
Gross profit margin for the third quarter of fiscal 2019 was 57.7%, compared with 57.6% for the prior-year period.
Sales, marketing and administrative (SG&A) expenses for the third quarter of fiscal 2019 were $7.9 million, compared with $5.7 million for the prior-year quarter. The increase was primarily due to higher headcount in accounting, marketing, administrative support and other functions necessary to support growth.
Research and development (R&D) expenses for the third quarter of fiscal 2019 were $1.5 million, compared with $367,000 a year ago, with the increase primarily driven by higher spending to develop improved processing methods for the Company’s human cell and tissue products, as well as continued development of diagnostic products.
Amortization and depreciation expenses for the third quarter of fiscal 2019 were $2.4 million, compared with $1.1 million for the prior-year period, with the increase primarily due to an increase in the intangible asset portfolio arising from the business combinations and asset acquisition.
The net loss attributable to controlling interest for the third quarter of fiscal 2019 was $3.7 million, or $0.01 per share, compared with a net loss attributable to controlling interest for the third quarter of fiscal 2018 of $3.2 million, or $0.01 per share.
Year-to-date Financial Results
Revenue for the first nine months of fiscal 2019 was $30.0 million, a 217% increase from $9.5 million for the first nine months of fiscal 2018. Gross profit margin for first nine months of fiscal 2019 was 63.8%, an improvement from 62.5% from the prior-year period.
SG&A expenses for the nine months ended March 31, 2019 were $19.1 million, compared with $14.7 million for the nine months ended March 31, 2018, with the increase due to higher headcount in sales and general and administrative functions as the Company continues to expand, as well as increasing public company compliance costs.
R&D expenses for the first nine months of fiscal 2019 were $3.8 million, compared with $417,000 for the prior-year period, with the increase due to costs related to internal development of existing products, and an increased focus in developing DNA diagnostics and new methods for processing tissues.
Depreciation and amortization expenses for the nine months ended March 31, 2019 were $6.1 million, compared with $3.4 million for the prior-year period, with the increase primarily due to a laboratory buildout and related laboratory equipment purchases, computer hardware and software purchases, and intangible assets arising from acquisitions.
Other expense, net for the nine months ended March 31, 2019 was $832,000, compared with other income, net of $178,000 for the prior-year period. The change was primarily driven by increased losses from equity method investment caused by increasing ownership in Juneau Biosciences, LLC, partially offset by the bargain purchase gain arising from the acquisition of Taueret Laboratories, LLC.
The net loss attributable to controlling interest for the first nine months of fiscal 2019 was $8.0 million, or $0.03 per share, versus a net loss attributable to controlling interest for the first nine months of fiscal 2018 of $7.5 million, or $0.03 per share.
Cash and cash equivalents as of March 31, 2019 were $1.8 million, compared with $1.2 million as of June 30, 2018. Cash provided by operating activities for or the nine months ended March 31, 2019 was $3.1 million, a $5.7 million improvement from cash used in operating activities of $2.6 million for the nine months ended March 31, 2018.
Revisions of Previously Issued Financial Statements: During the financial close for the third fiscal quarter of 2019 the Company discovered errors in the Company’s accounting for income taxes, primarily with regard to impact of income taxes on the Company’s accounting for business combinations and asset acquisitions. The errors were determined to be material to the Company’s consolidated balance sheets, consolidated statements of operations, consolidated statement of stockholders’ equity, and statements of cash flows for the years ended June 30, 2018 and June 30, 2017. The financial information for prior periods has been restated to reflect these adjustments.
About Predictive Biotech, Inc.
Predictive Biotech, Inc., a Salt Lake City life sciences company formed in 2015, is a leader in human cell and tissue products for use in cellular therapies and regenerative medicine. A growing national network of clinics, health systems, researchers and physicians leverage Predictive’s four main placental-derived and Wharton’s jelly umbilical cord-derived products. Predictive Biotech’s current products are regulated by the FDA under 21 CFR part 1271 section 361 as minimally manipulated allografts intended for homologous use.
About Predictive Laboratories, Inc.
Predictive Laboratories owns significant next-generation sequencing and genotyping assets along with extensive protocols, quality and laboratory management systems and other resources required by a “high complexity” molecular diagnostic laboratory operating under the Clinical Laboratory Improvement Act (CLIA). In 2018 this group launched its novel test for women experiencing infertility, called ARTGuide™, to select beta launch centers. ARTGuide™ is a proprietary gene test panel for women experiencing infertility as a result of endometriosis and other health concerns. The test is expected to change the way that advanced reproductive technologies such as in vitro fertilization (IVF) are used to assist couples having difficulty conceiving a pregnancy.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively. Additional information is available at Predtechgroup.com; Predrx.com; Predictivebiotech.com; and Predictivelabs.com.
Forward-Looking Statements
This release contains “forward-looking” statements that are based on present circumstances and on Predictive Technology Group’s predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements and any statements of the plans and objectives of management for future operations and forecasts of future growth and value, are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements. Such forward-looking statements are made only as of the date of this release and Predictive Technology Group assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. The information in this press release should be read in conjunction with, and is modified in its entirety by, the Registration Statement on Form 10 (the “Form 10”) filed by the Predictive Technology Group with the Securities and Exchange Commission (the “SEC”) and all of the Company’s other public filings with the SEC (the “Public Filings”). In particular, the financial information contained herein is subject to and qualified by reference to the financial statements contained in the Form 10 and Public Filings, the footnotes thereto and the limitations set forth therein. Investors may not rely on the press release without reference to the Form 10 and the Public Filings.
Contact:
Investors
LHA Investor Relations
Jody Cain jcain@lhai.com
Kevin Mc Cabe kmccabe@lhai.com
310-691-7100
1-2 weeks is a good guess as we're in Day 19 of their proposal to uplist, which is said to take 4-6 weeks. Barring no hiccups, I don't see why it doesn't happen...
I’m just adding again at $3.50. Hope I get to do it again, today...
Griping Stocks: Predictive Technology Group Inc (OTC US
RED)
By
David Holmes -
May 23, 20190
83
On 22-05-2019 (Wednesday), the shares-rate of the Company Predictive Technology Group Inc, PRED exchange OTC US, is an exciting player in the Medical.
Analyst Summary Of The Predictive Technology Group IncIn Stock Exchange OTC US:
ThePredictive Technology Group Inc (OTC US: PRED) opened the business at 3.51 and closed at 3.43 with the change of -0.09 during the period of last trading session.
Trading Gap-Up & Gap-Down with Prices (High & Low):
The current high trading price remained at Predictive Technology Group Inc while previous high price was 4.17 and current low trading price remained Predictive Technology Group Inc while previous low price was 3.41 at which stock traded during the course of the day. It is mandatory for investors to know the trading comparison of current & last day sessions. The Gap-Up -0.66 is the difference between the current session’s open and the previous session’s High and Gap-up percentage became -0.16% Similarly, the Gap-Down $0.1 is the difference between the current session’s open and the previous session’s Low and Gap-down percentage became 0.03%.
Volume Indicator:
Trading volume can help an investor to identify the momentum in a stock and confirm a trend. If trading volume increases, prices generally moves in the same direction. That is, if a security is continuing higher in an uptrend, the volume of the security should also increase and vice versa. The Company’s current volume remained at 570700 with the percent of 0.37%. It will also better to share yesterday’s volume of the company i.e.; 614900.
Market Capitalization:
Market Capitalization is the true measure of a company’s value. There’s a common mis-conception that a company’s per-share stock price holds as much importance as its market capitalization when it comes to choosing stocks to purchase. This fallacy occurs especially often in the case of new investors. The market Capitalization of the company recorded at 959323000.
Highest & Lowest Prices Of OTC US,Predictive Technology Group Inc With Moving Average:
A high/low is the highest and lowest price at which a stock has traded during the previous week (05-days). It is a technical indicator used by buyer / seller and investors who view the previous week high or low as an important aspect in determining a stock’s current value and predicting future price movement. The highest price over the last 05 days was remained at 4.6 with the high parentage of -0.25. The Lowest price over the last 05 days was remained at 3.18with the low percentage of 0.08.
A Moving Average (MA) is a comprehensively indicator and is based on past price.
05 Days Moving Average (MA): 3.93%
20 Days Moving Average (MA) & Signals: 3.3177%
50 Days Moving Average (MA) & Signals: 2.6578%
Weighted Alpha:
Weighted Alpha alert that stock has increased or decreased over an one-year period with a higher weighting for recent price activity. The company’s Predictive Technology Group Inc has a Weighted Aplha 38.60.
Return on Equity (ROE)%:
ROE is considered a measure of how effectively management is using a company’s assets to create profits. ROE is expressed as a percentage and can be calculated for any company if net income and equity are both positive numbers. The company Predictive Technology Group Inc having 0%.
PE (TTM):
TTM stands for Trailing Twelve Months. It is being used to represent the performance of Predictive Technology Group Inc. The Price/Earnings Ratio is often referred to as P/E (ttm), which is calculated as the stock’s current price divided by a company’s trailing 12-month Earnings per Share (EPS). The PE(ttm) of the Company recorded at 0%.
· Forward PE Ratio
A company with a higher forward P/E ratio than the industry or market average indicates an expectation the company is likely to experience a significant amount of growth. If a company’s stock fails to meet the high ratio value with increased per share earnings, the price of the stock will fall. The forward P/E ratio of Predictive Technology Group Inc, OTC US recorded as 0.00%.
https://nysenewsanalyst.com/2019/05/23/griping-stocks-predictive-technology-group-inc-otc-uspred/
RED)By
David Holmes -
May 23, 20190
83
On 22-05-2019 (Wednesday), the shares-rate of the Company Predictive Technology Group Inc, PRED exchange OTC US, is an exciting player in the Medical.
Analyst Summary Of The Predictive Technology Group IncIn Stock Exchange OTC US:
ThePredictive Technology Group Inc (OTC US: PRED) opened the business at 3.51 and closed at 3.43 with the change of -0.09 during the period of last trading session.
Trading Gap-Up & Gap-Down with Prices (High & Low):
The current high trading price remained at Predictive Technology Group Inc while previous high price was 4.17 and current low trading price remained Predictive Technology Group Inc while previous low price was 3.41 at which stock traded during the course of the day. It is mandatory for investors to know the trading comparison of current & last day sessions. The Gap-Up -0.66 is the difference between the current session’s open and the previous session’s High and Gap-up percentage became -0.16% Similarly, the Gap-Down $0.1 is the difference between the current session’s open and the previous session’s Low and Gap-down percentage became 0.03%.
Volume Indicator:
Trading volume can help an investor to identify the momentum in a stock and confirm a trend. If trading volume increases, prices generally moves in the same direction. That is, if a security is continuing higher in an uptrend, the volume of the security should also increase and vice versa. The Company’s current volume remained at 570700 with the percent of 0.37%. It will also better to share yesterday’s volume of the company i.e.; 614900.
Market Capitalization:
Market Capitalization is the true measure of a company’s value. There’s a common mis-conception that a company’s per-share stock price holds as much importance as its market capitalization when it comes to choosing stocks to purchase. This fallacy occurs especially often in the case of new investors. The market Capitalization of the company recorded at 959323000.
Highest & Lowest Prices Of OTC US,Predictive Technology Group Inc With Moving Average:
A high/low is the highest and lowest price at which a stock has traded during the previous week (05-days). It is a technical indicator used by buyer / seller and investors who view the previous week high or low as an important aspect in determining a stock’s current value and predicting future price movement. The highest price over the last 05 days was remained at 4.6 with the high parentage of -0.25. The Lowest price over the last 05 days was remained at 3.18with the low percentage of 0.08.
A Moving Average (MA) is a comprehensively indicator and is based on past price.
05 Days Moving Average (MA): 3.93%
20 Days Moving Average (MA) & Signals: 3.3177%
50 Days Moving Average (MA) & Signals: 2.6578%
Weighted Alpha:
Weighted Alpha alert that stock has increased or decreased over an one-year period with a higher weighting for recent price activity. The company’s Predictive Technology Group Inc has a Weighted Aplha 38.60.
Return on Equity (ROE)%:
ROE is considered a measure of how effectively management is using a company’s assets to create profits. ROE is expressed as a percentage and can be calculated for any company if net income and equity are both positive numbers. The company Predictive Technology Group Inc having 0%.
PE (TTM):
TTM stands for Trailing Twelve Months. It is being used to represent the performance of Predictive Technology Group Inc. The Price/Earnings Ratio is often referred to as P/E (ttm), which is calculated as the stock’s current price divided by a company’s trailing 12-month Earnings per Share (EPS). The PE(ttm) of the Company recorded at 0%.
· Forward PE Ratio
A company with a higher forward P/E ratio than the industry or market average indicates an expectation the company is likely to experience a significant amount of growth. If a company’s stock fails to meet the high ratio value with increased per share earnings, the price of the stock will fall. The forward P/E ratio of Predictive Technology Group Inc, OTC US recorded as 0.00%.
https://nysenewsanalyst.com/2019/05/23/griping-stocks-predictive-technology-group-inc-otc-uspred/
PRED featured again HB target 6.5 https://www.thetechtrader.com/chart...stocktwits&utm_medium=social&utm_campaign=COD
